Powering the Immune System to Transform Lives
Suzanne L. Topalian, M.D.
Director
Suzanne L. Topalian, M.D., has served as a member of our Board since October 2026.
Dr. Topalian is a physician-scientist and internationally recognized leader in cancer immunotherapy whose foundational research on anti-tumor immunity and PD-1 blockade helped establish immune checkpoint inhibition as a pillar of modern oncology. Her work demonstrated durable tumor regressions across multiple malignancies and laid the clinical foundation for today’s PD 1/PD L1 inhibitors, now approved in more than 20 cancer types.
Since 2018, she has been the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine.* She also serves as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director of the Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins.
She has authored more than 180 peer reviewed publications and is one of the most highly cited biomedical researchers. Dr. Topalian’s work has garnered numerous awards, and she was recognized with election to the National Academy of Medicine in 2017 and the American Association for Cancer Research (AACR) Academy in 2022.
Dr. Topalian holds a B.A. in English from Wellesley College. She received her M.D. from Tufts University School of Medicine and completed postgraduate training in general surgery at Thomas Jefferson University Hospital and surgical oncology at the National Institutes of Health.
*Participation by Dr. Topalian (as a director of Vir Biotechnology) does not constitute or imply endorsement of Vir Biotechnology by Johns Hopkins University.